Cel Sci CVM
NYSE CVM
$1.42 -0.04 (-2.74%)
At close: Aug 21, 2026 · 4:00 PM EDT

Cel Sci (CVM) Total Non-Current Liabilities (2010 - 2026)

Cel Sci (CVM) posted Total Non-Current Liabilities of $10.7 million for Q1 2026, down 7.94% sequentially from $11.6 million in Q4 2025, and down 21.75% YoY from $13.7 million in Q1 2025.

Cel Sci (CVM) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends

Cel Sci has reported Total Non-Current Liabilities for 16 years, with the latest figure at $10.7 million in Q1 2026.

  • Quarterly Total Non-Current Liabilities fell 21.75% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 21.75% YoY) and the FY2025 annual result came in at $12.1 million, down 13.76% from the prior year.
  • Total Non-Current Liabilities slipped to $10.7 million in Q1 2026 per CVM's latest filing, from $11.6 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $18.9 million in Q1 2022 and troughed at $10.7 million in Q1 2026.
  • A 5-year average of $15.4 million and a median of $15.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities climbed 12.88% in 2022, then slipped 21.75% in 2026.
  • Over 5 years, Total Non-Current Liabilities stood at $17.8 million in 2022, then dropped by 10.68% to $15.9 million in 2023, then fell by 10.48% to $14.3 million in 2024, then dropped by 18.47% to $11.6 million in 2025, then slipped by 7.94% to $10.7 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $10.7 million, $11.6 million, and $12.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 3.92 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 1.88 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 4.20 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 724.15 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 1.17 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 9.32 Bn
10 Cel Sci 2.12 Mn -4.42 Mn - 10.27 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 10.71 Mn
Dec 31, 2025 11.63 Mn
Sep 30, 2025 12.07 Mn
Jun 30, 2025 13.19 Mn
Mar 31, 2025 13.68 Mn
Dec 31, 2024 14.27 Mn
Sep 30, 2024 14.00 Mn
Jun 30, 2024 15.47 Mn
Mar 31, 2024 15.62 Mn
Dec 31, 2023 15.93 Mn
Sep 30, 2023 17.19 Mn
Jun 30, 2023 17.40 Mn
Mar 31, 2023 17.92 Mn
Dec 31, 2022 17.84 Mn
Sep 30, 2022 18.24 Mn
Jun 30, 2022 18.04 Mn
Mar 31, 2022 18.91 Mn
Dec 31, 2021 18.20 Mn
Sep 30, 2021 19.21 Mn
Jun 30, 2021 19.72 Mn